E-viri
Recenzirano
Odprti dostop
-
Mehrotra, Devan V; Janes, Holly E; Fleming, Thomas R; Annunziato, Paula W; Neuzil, Kathleen M; Carpp, Lindsay N; Benkeser, David; Brown, Elizabeth R; Carone, Marco; Cho, Iksung; Donnell, Deborah; Fay, Michael P; Fong, Youyi; Han, Shu; Hirsch, Ian; Huang, Ying; Huang, Yunda; Hyrien, Ollivier; Juraska, Michal; Luedtke, Alex; Nason, Martha; Vandebosch, An; Zhou, Honghong; Cohen, Myron S; Corey, Lawrence; Hartzel, Jonathan; Follmann, Dean; Gilbert, Peter B
Annals of internal medicine, 02/2021, Letnik: 174, Številka: 2Journal Article
Several vaccine candidates to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) have entered or will soon enter large-scale, phase 3, placebo-controlled randomized clinical trials. To facilitate harmonized evaluation and comparison of the efficacy of these vaccines, a general set of clinical endpoints is proposed, along with considerations to guide the selection of the primary endpoints on the basis of clinical and statistical reasoning. The plausibility that vaccine protection against symptomatic COVID-19 could be accompanied by a shift toward more SARS-CoV-2 infections that are asymptomatic is highlighted, as well as the potential implications of such a shift.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.